{"id":"https://openalex.org/W2252870058","doi":"https://doi.org/10.2217/fon.15.363","title":"Servier\u2019s Pipeline in Oncology: Moving from Research to Patients","display_name":"Servier\u2019s Pipeline in Oncology: Moving from Research to Patients","publication_year":2016,"publication_date":"2016-01-14","ids":{"openalex":"https://openalex.org/W2252870058","doi":"https://doi.org/10.2217/fon.15.363","mag":"2252870058","pmid":"https://pubmed.ncbi.nlm.nih.gov/26764971"},"language":"en","primary_location":{"id":"doi:10.2217/fon.15.363","doi":"https://doi.org/10.2217/fon.15.363","is_oa":true,"landing_page_url":"https://doi.org/10.2217/fon.15.363","pdf_url":"https://www.futuremedicine.com/doi/pdf/10.2217/fon.15.363","source":{"id":"https://openalex.org/S174572715","display_name":"Future Oncology","issn_l":"1479-6694","issn":["1479-6694","1744-8301"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310321119","host_organization_name":"Future Medicine","host_organization_lineage":["https://openalex.org/P4310321119"],"host_organization_lineage_names":["Future Medicine"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Future Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://www.futuremedicine.com/doi/pdf/10.2217/fon.15.363","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5109912291","display_name":"Patrick Therasse","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405268767","display_name":"Institut de Recherches Internationales Servier (France)","ror":"https://ror.org/01zej3n42","country_code":"FR","type":"company","lineage":["https://openalex.org/I4405268767"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Patrick Therasse","raw_affiliation_strings":["Oncology PIT, IRIS, 50 Rue Carnot, 92284, Suresnes, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology PIT, IRIS, 50 Rue Carnot, 92284, Suresnes, France","institution_ids":["https://openalex.org/I4405268767"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5109028993","display_name":"Jean\u2010Pierre Abastado","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405268767","display_name":"Institut de Recherches Internationales Servier (France)","ror":"https://ror.org/01zej3n42","country_code":"FR","type":"company","lineage":["https://openalex.org/I4405268767"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Jean-Pierre Abastado","raw_affiliation_strings":["Oncology PIT, IRIS, 50 Rue Carnot, 92284, Suresnes, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology PIT, IRIS, 50 Rue Carnot, 92284, Suresnes, France","institution_ids":["https://openalex.org/I4405268767"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4405268767"],"apc_list":null,"apc_paid":null,"fwci":0.3592,"has_fulltext":true,"cited_by_count":3,"citation_normalized_percentile":{"value":0.6746911,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":94},"biblio":{"volume":"12","issue":"5","first_page":"589","last_page":"594"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9556000232696533,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9556000232696533,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.006000000052154064,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T13656","display_name":"Science, Research, and Medicine","score":0.005400000140070915,"subfield":{"id":"https://openalex.org/subfields/2743","display_name":"Reproductive Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/anticancer-drug-development","display_name":"anticancer drug development","score":0.906000018119812},{"id":"https://openalex.org/keywords/drug-pipeline","display_name":"drug development pipeline","score":0.5350000262260437},{"id":"https://openalex.org/keywords/translational-research","display_name":"translational research","score":0.7160000205039978},{"id":"https://openalex.org/keywords/recist","display_name":"RECIST","score":0.871999979019165},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.5730000138282776},{"id":"https://openalex.org/keywords/tumor-immune-microenvironment","display_name":"tumor immune microenvironment","score":0.7620000243186951},{"id":"https://openalex.org/keywords/servier","display_name":"Servier","score":0.4729999899864197}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6214547157287598},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5152883529663086},{"id":"https://openalex.org/C2776598537","wikidata":"https://www.wikidata.org/wiki/Q1812651","display_name":"Clinical Oncology","level":3,"score":0.45102235674858093},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4384698271751404},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.38088667392730713},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3337818384170532}],"mesh":[{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003131","descriptor_name":"Combined Modality Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004345","descriptor_name":"Drug Industry","qualifier_ui":"Q000458","qualifier_name":"organization & administration","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007167","descriptor_name":"Immunotherapy","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D007546","descriptor_name":"Isoquinolines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D007546","descriptor_name":"Isoquinolines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008228","descriptor_name":"Lymphoma, Non-Hodgkin","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D008228","descriptor_name":"Lymphoma, Non-Hodgkin","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008495","descriptor_name":"Medical Oncology","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D015202","descriptor_name":"Protein Engineering","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017209","descriptor_name":"Apoptosis","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D017326","descriptor_name":"Clinical Trials, Phase III as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D055808","descriptor_name":"Drug Discovery","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D055818","descriptor_name":"Public-Private Sector Partnerships","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D057170","descriptor_name":"Translational Research, Biomedical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D057285","descriptor_name":"Precision Medicine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D059005","descriptor_name":"Topoisomerase II Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D059005","descriptor_name":"Topoisomerase II Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D064987","descriptor_name":"Cell- and Tissue-Based Therapy","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.2217/fon.15.363","doi":"https://doi.org/10.2217/fon.15.363","is_oa":true,"landing_page_url":"https://doi.org/10.2217/fon.15.363","pdf_url":"https://www.futuremedicine.com/doi/pdf/10.2217/fon.15.363","source":{"id":"https://openalex.org/S174572715","display_name":"Future Oncology","issn_l":"1479-6694","issn":["1479-6694","1744-8301"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310321119","host_organization_name":"Future Medicine","host_organization_lineage":["https://openalex.org/P4310321119"],"host_organization_lineage_names":["Future Medicine"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Future Oncology","raw_type":"journal-article"},{"id":"pmid:26764971","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26764971","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Future oncology (London, England)","raw_type":"Interview"}],"best_oa_location":{"id":"doi:10.2217/fon.15.363","doi":"https://doi.org/10.2217/fon.15.363","is_oa":true,"landing_page_url":"https://doi.org/10.2217/fon.15.363","pdf_url":"https://www.futuremedicine.com/doi/pdf/10.2217/fon.15.363","source":{"id":"https://openalex.org/S174572715","display_name":"Future Oncology","issn_l":"1479-6694","issn":["1479-6694","1744-8301"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310321119","host_organization_name":"Future Medicine","host_organization_lineage":["https://openalex.org/P4310321119"],"host_organization_lineage_names":["Future Medicine"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Future Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.8048999905586243,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2252870058.pdf","grobid_xml":"https://content.openalex.org/works/W2252870058.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2947114971","https://openalex.org/W2894488999","https://openalex.org/W2790056391","https://openalex.org/W3174049883","https://openalex.org/W2963871989","https://openalex.org/W2965511607","https://openalex.org/W3202666085","https://openalex.org/W2917948849","https://openalex.org/W2076163094","https://openalex.org/W4404373794"],"abstract_inverted_index":{"Patrick":[0,12],"Therasse":[1,13],"and":[2,69,78,113,156,192,214,236,291],"Jean-Pierre":[3,159],"Abastado":[4,160],"speak":[5],"to":[6],"Roshaine":[7],"Gunawardana,":[8],"Managing":[9],"Commissioning":[10],"Editor:":[11],"is":[14,29,117,161,175],"an":[15,162],"MD,":[16,222],"PhD":[17,204],"who":[18],"has":[19,92,282,302],"focused":[20],"his":[21,61,186,203,274],"career":[22,62,188],"on":[23,205,284],"drug":[24,148],"development":[25,149],"in":[26,94,107,135,164,169,182,228,252,292],"oncology.":[27],"He":[28,59,91,116,184,195,224,240,281,301],"currently":[30],"the":[31,64,84,108,130,167,178,211,229,233,238,262,268,277,285,293],"Head":[32,52],"of":[33,53,71,83,97,104,110,143,166,177,232,247,264,288,297],"Oncology":[34,170],"Development":[35,56],"for":[36,40,46,57,67,88,121,132],"Servier.":[37],"Before":[38,257],"working":[39],"Servier,":[41,172,259],"he":[42,174,260],"worked":[43,93],"8":[44],"years":[45],"GlaxoSmithKline":[47],"Vaccines":[48],"as":[49,74,81],"Vice":[50,242],"President,":[51,243],"Global":[54],"Clinical":[55],"immunotherapeutics.":[58],"started":[60],"at":[63,171,198,210,219,237],"European":[65],"Organization":[66],"Research":[68,86],"Treatment":[70],"Cancer":[72],"(EORTC)":[73],"a":[75,100,216,249],"research":[76],"fellow":[77],"then":[79],"served":[80,283],"Director":[82,176],"EORTC":[85],"Center":[87],"11":[89],"years.":[90],"all":[95],"fields":[96],"oncology":[98],"with":[99,150],"long":[101],"track":[102],"record":[103],"publications":[105],"mainly":[106],"field":[109],"breast":[111],"cancer":[112,136],"methodological":[114],"research.":[115,158],"most":[118],"well":[119],"known":[120],"developing":[122],"new":[123],"Response":[124],"Criteria":[125],"In":[126],"Solid":[127],"Tumours":[128],"(RECIST),":[129],"reference":[131],"response":[133],"assessment":[134],"clinical":[137],"trials":[138],"since":[139],"2000.":[140],"His":[141],"areas":[142],"expertise":[144],"encompass":[145],"Phase":[146],"I\u2013III":[147],"small":[151],"molecules":[152],"or":[153],"active/passive":[154],"immunotherapy":[155],"translational":[157],"immuno-oncologist":[163],"charge":[165],"R&D":[168],"where":[173,273],"Therapeutic":[179],"Innovation":[180],"Pole":[181],"Oncology.":[183],"conducted":[185],"professional":[187],"between":[189],"various":[190],"academic":[191],"industrial":[193],"institutions.":[194],"was":[196,241],"trained":[197],"Ecole":[199],"Polytechnique":[200],"(Paris),":[201],"prepared":[202],"Major":[206],"Histocompatibility":[207],"Complex":[208],"(MHC)":[209],"Pasteur":[212,234],"Institute,":[213],"made":[215],"postdoctoral":[217],"training":[218],"NIH":[220],"(Bethesda,":[221],"USA).":[223],"studied":[225,276],"T-cell":[226],"activation":[227],"Immunology":[230,266,270],"department":[231],"Institute":[235],"CNRS.":[239],"Chief":[244],"Scientific":[245,294],"Officer":[246],"IDM-Pharma,":[248],"company":[250],"specialized":[251],"cell":[253],"therapy":[254],"against":[255],"cancer.":[256],"joining":[258],"headed":[261],"Laboratory":[263],"Tumour":[265],"within":[267],"Singapore":[269],"Network":[271],"(SIgN)":[272],"team":[275],"tumor":[278],"immune":[279],"microenvironment.":[280],"Editorial":[286],"board":[287],"several":[289,298],"journals":[290],"Advisory":[295],"Board":[296],"biotech":[299],"companies.":[300],"authored":[303],"more":[304],"than":[305],"120":[306],"peer-reviewed":[307],"publications.":[308]},"counts_by_year":[{"year":2020,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}